157 related articles for article (PubMed ID: 8180015)
1. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J
Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant KL; Brogden RN; Pilkington T; Faulds D
Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Scheulen ME; Niederle N; Bremer K; Schütte J; Seeber S
Cancer Treat Rev; 1983 Sep; 10 Suppl A():93-101. PubMed ID: 6414700
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
5. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas.
Niederle N; Scheulen ME; Cremer M; Schütte J; Schmidt CG; Seeber S
Cancer Treat Rev; 1983 Sep; 10 Suppl A():129-35. PubMed ID: 6627239
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced malignancies with ifosfamide under protection with mesna.
Li GC; Brock N; Li JQ; Guan ZZ; He YJ
Int J Clin Pharmacol Res; 1988; 8(1):55-67. PubMed ID: 3130316
[TBL] [Abstract][Full Text] [Related]
8. Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.
Munshi NC; Loehrer PJ; Williams SD; Langefeld C; Sledge G; Nichols CR; Roth BJ; Neuman A; Walsh WB; Einhorn LH
Invest New Drugs; 1992 Aug; 10(3):159-63. PubMed ID: 1428725
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
Katz A; Epelman S; Anelli A; Gorender EF; Cruz SM; Oliveira RM; Marques LA
J Cancer Res Clin Oncol; 1995; 121(2):128-31. PubMed ID: 7883776
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.
Jäger AH; Bogdahn U; Apfel R; Pfeufer B; Dekant A
J Cancer Res Clin Oncol; 1993; 119(12):721-6. PubMed ID: 8408185
[TBL] [Abstract][Full Text] [Related]
12. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
Bokemeyer C; Fels LM; Dunn T; Voigt W; Gaedeke J; Schmoll HJ; Stolte H; Lentzen H
Br J Cancer; 1996 Dec; 74(12):2036-41. PubMed ID: 8980410
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide and mesna.
Med Lett Drugs Ther; 1989 Nov; 31(804):98-9. PubMed ID: 2554100
[No Abstract] [Full Text] [Related]
14. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
Cervellino JC; Araujo CE; Pirisi C; Francia A; Cerruti R
Oncology; 1991; 48(2):89-92. PubMed ID: 1900124
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
Turrill M; Spicer DV; Kelley AS; Herman RL; Russell CA; Muggia FM
Cancer Invest; 1995; 13(2):160-4. PubMed ID: 7874569
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Zidar BL; Metch B; Balcerzak SP; Pierce HI; Militello L; Keppen MD; Berenberg JL
Cancer; 1992 Nov; 70(10):2547-51. PubMed ID: 1423183
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide and mesna.
Schoenike SE; Dana WJ
Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Miser JS; Kinsella TJ; Triche TJ; Tsokos M; Jarosinski P; Forquer R; Wesley R; Magrath I
J Clin Oncol; 1987 Aug; 5(8):1191-8. PubMed ID: 3114435
[TBL] [Abstract][Full Text] [Related]
20. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
